Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Taiwan / NCT06596174
Recruiting Not applicable

Effect of tSCS on Ankle Movement Training in Individuals With SCI

NCT06596174 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2024-11-25
Last updated
2024-11-26

Condition(s) studied

SCI - Spinal Cord Injury

Investigational drug(s) / intervention(s)

Transcutaneous spinal cord stimulation (tSCS)Short-term Machine-Assisted Ankle Movement Training with tSCSLong-term Effects of Machine-Assisted Ankle Movement Training with tSCS

Transcutaneous spinal cord stimulation (tSCS): The subjects will undergo 20 minutes transcutaneous spinal cord stimulation (tSCS).

Short-term Machine-Assisted Ankle Movement Training with tSCS: The subjects will undergo 30 minutes of machine-assisted ankle movement training combined with transcutaneous spinal cord stimulation (tSCS) at a time

Long-term Effects of Machine-Assisted Ankle Movement Training with tSCS: The subjects will undergo machine-assisted ankle movement training combined with transcutaneous spinal cord stimulation (tSCS). Each session will last for 30 minutes, conducted three times per week, over a period of four weeks.

Study summary

This clinical trial explores the effectiveness of transcutaneous spinal cord stimulation (tSCS), a non-invasive technique, in facilitating spinal circuitry adaptation in individuals with spinal cord injury (SCI). While epidural spinal cord stimulation (eSCS) has shown functional benefits, its application is limited by the side effects associated with implanted electrodes. tSCS, which shares a similar mechanism but does not require surgery, has yet to be extensively studied in large human trials.

The study aims to:

Determine optimal tSCS parameters for non-invasive spinal stimulation. Investigate the priming effect of tSCS on spinal circuitry during machine-assisted ankle movement training.

Examine the long-term clinical outcomes of combining tSCS with ankle movement training in individuals with incomplete SCI.

The trial will include both healthy participants and individuals with complete and incomplete SCI, using the soleus post-activation depression (PAD) model to evaluate spinal circuitry adaptation. The results will provide insights into spinal re-adaptation and potentially introduce a novel, non-invasive approach for SCI rehabilitation.

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
Accepted
Health subjects: Exclusion Criteria: 1. Musculoskeletal injuries on legs. 2. Osteoporosis. SCI subjects: Inclusion Criteria 1\. Participants with chronic spinal cord injury, with injury duration greater than one year. Exclusion Criteria 1. Current musculoskeletal or joint injuries in the lower limbs. 2. History of central or peripheral neuromuscular diseases. 3. Presence of a pacemaker. 4. Current use of antispastic or antidepressant medications. 5. Current venous thromboembolism or osteoporosis. 6. Impairment of the soleus H-reflex arc.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chang Gung University Taoyuan Taiwan Recruiting

More Chang Gung University trials in Taiwan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06596174 on ClinicalTrials.gov ↗ ← All trials in Taiwan